• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

COA Announces Opposition to Administration Nixing Part D Rebate Rule

Article

Community Oncology Alliance's (COA's) executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care.

Community Oncology Alliance's executive director Ted Okon has released a statement expressing disappointment over the Trump administration’s decision to abandon a proposed rule to eliminate rebates in Medicare Part D and Medicaid managed care. According to Okon, the proposed rule would have lowered drug prices for patients by ensuring they receive the benefit of negotiated drug discounts. By nixing the proposed rule, the administration has handed a gift to pharmacy benefit managers (PBMs).

In the original plan’s announcement, President Donald Trump and HHS Secretary Alex Azar acknowledged that “nearly every drug company taking a January 2019 price increase announced that all of the increase was being paid to PBMs or insurers as rebates.”

Read the full press release.

Related Videos
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Robert Zimmerman, MD
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Kimberly Westrich, MA
Dr Kevin Mallow, PharmD, BCPS, BC-ADM, CDCES
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.